Roxithromycin monotherapy inducing a partial response in a patient with myeloma: a case report

BACKGROUND: Clarithromycin is an efficacious treatment for myeloma in combination with other anti-myeloma therapy but not as monotherapy. To date, all studies have focused on a clarithromycin-specific effect rather than a class effect (macrolide) and there is no information on the activity of roxith...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Kern Y., Byrne, Anna L., Morison, Ian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944102/
https://www.ncbi.nlm.nih.gov/pubmed/29743095
http://dx.doi.org/10.1186/s13256-018-1636-9
Descripción
Sumario:BACKGROUND: Clarithromycin is an efficacious treatment for myeloma in combination with other anti-myeloma therapy but not as monotherapy. To date, all studies have focused on a clarithromycin-specific effect rather than a class effect (macrolide) and there is no information on the activity of roxithromycin in myeloma. CASE PRESENTATION: Here we report an untreated 86-year-old New Zealand European white man with IgA myeloma whose paraprotein decreased by 57%, consistent with a partial response, after a course of roxithromycin for pneumonia. His paraprotein reduced from 46 to 20 g/L while his hemoglobin improved from 97 to 123 g/L after 1 month. CONCLUSION: Additional investigations should be considered to elucidate the therapeutic effect of roxithromycin in myeloma.

Ejemplares similares